Univariable Fine-Gray competing risk analysis for the development of major ICH
| . | HR . | 95% CI . | P . |
|---|---|---|---|
| Age at diagnosis, y | 1.04 | 1.00-1.08 | .05 |
| Hypertension | 1.03 | 0.33-3.21 | .96 |
| Surgical resection | 0.94 | 0.29-3.09 | .92 |
| Stereotactic radiosurgery | 0.74 | 0.20-2.70 | .65 |
| Aspirin use | 0.63 | 0.08-4.84 | .66 |
| Antiangiogenic agents | 0.95 | 0.31-2.90 | .92 |
| . | HR . | 95% CI . | P . |
|---|---|---|---|
| Age at diagnosis, y | 1.04 | 1.00-1.08 | .05 |
| Hypertension | 1.03 | 0.33-3.21 | .96 |
| Surgical resection | 0.94 | 0.29-3.09 | .92 |
| Stereotactic radiosurgery | 0.74 | 0.20-2.70 | .65 |
| Aspirin use | 0.63 | 0.08-4.84 | .66 |
| Antiangiogenic agents | 0.95 | 0.31-2.90 | .92 |